Illumina Inc. (ILMN) Given “Neutral” Rating at BTIG Research
Illumina Inc. (NASDAQ:ILMN)‘s stock had its “neutral” rating reiterated by research analysts at BTIG Research in a research report issued to clients and investors on Wednesday.
ILMN has been the subject of several other research reports. Zacks Investment Research upgraded Illumina from a “sell” rating to a “hold” rating in a research note on Monday, July 4th. CL King downgraded Illumina from a “buy” rating to a “neutral” rating in a research note on Monday, August 22nd. Piper Jaffray Cos. reiterated an “overweight” rating and set a $161.00 price target on shares of Illumina in a research note on Friday, July 15th. Vetr upgraded Illumina from a “sell” rating to a “buy” rating and set a $198.61 price target for the company in a research note on Monday, October 3rd. Finally, Cantor Fitzgerald cut their price target on Illumina from $165.00 to $155.00 and set a “hold” rating for the company in a research note on Tuesday. Two analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $158.34.
Shares of Illumina (NASDAQ:ILMN) traded down 2.02% on Wednesday, reaching $136.18. The company’s stock had a trading volume of 2,882,037 shares. The stock has a market cap of $19.96 billion, a P/E ratio of 46.64 and a beta of 0.47. The firm’s 50-day moving average price is $174.01 and its 200-day moving average price is $156.43. Illumina has a 12 month low of $127.10 and a 12 month high of $196.47.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.13. The firm earned $600 million during the quarter, compared to the consensus estimate of $31.91 million. Illumina had a return on equity of 23.69% and a net margin of 18.73%. The business’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.80 EPS. On average, analysts forecast that Illumina will post $3.53 earnings per share for the current fiscal year.
In other Illumina news, Director Robert S. Epstein sold 1,200 shares of Illumina stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $150.00, for a total transaction of $180,000.00. Following the completion of the transaction, the director now owns 7,824 shares in the company, valued at $1,173,600. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel Bradbury sold 600 shares of Illumina stock in a transaction on Friday, October 7th. The shares were sold at an average price of $184.36, for a total value of $110,616.00. Following the transaction, the director now owns 17,065 shares of the company’s stock, valued at approximately $3,146,103.40. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Glenmede Trust Co. NA boosted its position in Illumina by 26.2% in the first quarter. Glenmede Trust Co. NA now owns 3,660 shares of the life sciences company’s stock valued at $593,000 after buying an additional 760 shares in the last quarter. Virginia Retirement System acquired a new position in Illumina during the first quarter valued at $385,000. NN Investment Partners Holdings N.V. acquired a new position in Illumina during the first quarter valued at $403,000. Menta Capital LLC acquired a new position in Illumina during the first quarter valued at $603,000. Finally, Aviva PLC boosted its position in Illumina by 2.4% in the first quarter. Aviva PLC now owns 75,222 shares of the life sciences company’s stock valued at $12,194,000 after buying an additional 1,749 shares in the last quarter. Institutional investors and hedge funds own 95.22% of the company’s stock.
Illumina Company Profile
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.